MULTIBODY
LIVE

Serial Number

79209028

Owner

Crescendo Biologics Limited

Attorney

Christopher J. Schulte

Filing Date

Oct 21, 2016

Add to watchlist:

No watchlists yet
View on USPTO

MULTIBODY Trademark

Serial Number: 79209028 • Registration: 5450600

MULTIBODY is a trademark filed by Crescendo Biologics Limited on October 21, 2016. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Crescendo Biologics Limited (6 trademarks)

Meditrina Building,

Entity Type: 99

Trademark Details

Filing Date

October 21, 2016

Registration Date

April 24, 2018

Published for Opposition

February 6, 2018

Cancellation Date

November 8, 2024

Goods & Services

Treatment and transformation of materials, namely, custom manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing in the field of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of therapies using antibodies and antibody fragments

Chemicals used in industry and science; chemicals for laboratory research purposes; monoclonal antibodies and antibody fragments for scientific and laboratory use; monoclonal antibodies and antibody fragments for scientific research purposes; monoclonal antibody reagents for scientific and laboratory use; monoclonal antibodies and antibody fragments for scientific research purposes for use in the manufacture of therapeutic products

Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; monoclonal antibodies for therapeutic purposes, namely, therapeutic agents for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the manufacture of therapeutic products

Scientific and technological services, namely, scientific research, analysis and testing and research and design in the field of chemicals, biologicals, antibodies and antibody fragments; scientific laboratory services relating to antibodies and antibody fragments; research and development in the field of antibodies and antibody fragments; medical research laboratory services relating to antibodies and antibody fragments; engineering of antibodies and antibody fragments; scientific research relating to the discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, consulting in the field of antibody and antibody fragment design

Filing History

TOTAL INVALIDATION PROCESSED BY THE IB
Jan 22, 2026 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Dec 30, 2025 INTS
INVALIDATION PROCESSED
Dec 30, 2025 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Jul 8, 2025 INTR
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Jun 3, 2025 LIMN
CANCELLED SECTION 71
Nov 8, 2024 C71T
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
Nov 8, 2024 RHRD
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Oct 27, 2023 LIMN
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
Aug 19, 2023 RHRD
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Apr 24, 2023 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 7, 2018 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 9, 2018 FICS
FINAL DISPOSITION PROCESSED
Aug 9, 2018 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 24, 2018 FICR
REGISTERED-PRINCIPAL REGISTER
Apr 24, 2018 R.PR
PUBLISHED FOR OPPOSITION
Feb 6, 2018 PUBO
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 1, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 1, 2018 REAP
NOTICE OF PUBLICATION
Jan 17, 2018 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 28, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 21, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 21, 2017 CRFA
ASSIGNED TO LIE
Dec 19, 2017 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 12, 2017 TROA
NEW REPRESENTATIVE AT IB RECEIVED
Dec 7, 2017 NREP
REFUSAL PROCESSED BY IB
Jul 14, 2017 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 23, 2017 RFCS
REFUSAL PROCESSED BY MPU
Jun 22, 2017 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 14, 2017 RFCR
NON-FINAL ACTION WRITTEN
Jun 13, 2017 CNRT
APPLICATION FILING RECEIPT MAILED
Jun 9, 2017 MAFR
ASSIGNED TO EXAMINER
Jun 6, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 5, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 1, 2017 REPR